Scribd Logo
Upload

Welcome to Scribd!

  • Pharma - Oracle Concise Report

    Uploaded by

    PRAJWAL RASTOGI
    24 views1 page
    The pharmaceutical sector in India is large and growing rapidly. The domestic market is expected to reach $120-130 billion by 2030, up from $42 billion in 2021. The government has announced several policies to support the sector, including a $197 billion production linked incentive scheme over 5 years for key sectors. Major players in the industry include Sun Pharmaceuticals, which acquired rights to the drug Dapagliflozin, and Lupin Ltd, which is entering digital healthcare. The drivers of growth are low costs, economic expansion, and increasing investments, while risks include counterfeit drugs and limited rural infrastructure.

    Original Description:

    Original Title

    Pharma- Oracle Concise Report

    Copyright

    © © All Rights Reserved

    Available Formats

    PDF, TXT or read online from Scribd

    Did you find this document useful?

    Is this content inappropriate?

    Report this Document
    The pharmaceutical sector in India is large and growing rapidly. The domestic market is expected to reach $120-130 billion by 2030, up from $42 billion in 2021. The government has announced several policies to support the sector, including a $197 billion production linked incentive scheme over 5 years for key sectors. Major players in the industry include Sun Pharmaceuticals, which acquired rights to the drug Dapagliflozin, and Lupin Ltd, which is entering digital healthcare. The drivers of growth are low costs, economic expansion, and increasing investments, while risks include counterfeit drugs and limited rural infrastructure.

    Copyright:

    © All Rights Reserved
    Download as PDF, TXT or read online from Scribd
    Flag for inappropriate content
    Download as pdf or txt
    24 views1 page

    Pharma - Oracle Concise Report

    Uploaded by

    PRAJWAL RASTOGI
    The pharmaceutical sector in India is large and growing rapidly. The domestic market is expected to reach $120-130 billion by 2030, up from $42 billion in 2021. The government has announced several policies to support the sector, including a $197 billion production linked incentive scheme over 5 years for key sectors. Major players in the industry include Sun Pharmaceuticals, which acquired rights to the drug Dapagliflozin, and Lupin Ltd, which is entering digital healthcare. The drivers of growth are low costs, economic expansion, and increasing investments, while risks include counterfeit drugs and limited rural infrastructure.

    Copyright:

    © All Rights Reserved
    Download as PDF, TXT or read online from Scribd
    Flag for inappropriate content
    Download as pdf or txt
    of 1

    THE ORACLE CONCISE SERIES: PHARMACEUTICAL SECTOR

    Sector Size and composition Govt Policies Major Players in industry


    • According to the Indian Economic Survey 2021, the • In June 2021, FM Ms. Nirmala Sitharaman announced an
    domestic market is expected to grow 3x in the next •In June 2021, Sun Pharmaceuticals acquired the patent
    additional outlay of Rs. 197,000 crore that will be utilised license for Dapagliflozin from AstraZeneca. The company
    decade. India’s domestic pharmaceutical market is over five years for the pharmaceutical PLI scheme in 13 key will be distributing and promoting the drug under the
    estimated at US$ 42 billion in 2021 and likely to reach sectors. brand name ‘Oxra’.
    US$ 65 billion by 2024 and further expand to reach
    ~US$ 120-130 billion by 2030. • To achieve self-reliance and minimise import dependency in •In June 2021, Lupin Ltd. announced its intention to enter
    the country's essential bulk drugs, the Department of the digital healthcare space in India. It incorporated Lupin
    • India's biotechnology industry comprising Pharmaceuticals initiated a PLI scheme to promote
    biopharmaceuticals, bio-services, bio-agriculture, bio- Digital Health Ltd., a wholly owned subsidiary, to provide a
    domestic manufacturing by setting up greenfield plants digital therapeutics platform for medical practitioners and
    industry, and bioinformatics. The Indian biotechnology
    industry was valued at US$ 64 billion in 2019 and is patients in the country.
    • In May 2021, under Atmanirbhar Bharat 3.0, Mission COVID
    expected to reach US$ 150 billion by 2025. Suraksha was announced by the Government of India to •In May 2021, Cipla launched a real-time COVID-19
    accelerate development and production of indigenous detection kit ‘ViraGen’ that is based on multiplex
    • India’s medical devices market stood at US$ 10.36 COVID vaccines. polymerase chain reaction (PCR) technology.
    billion in FY20. The market is expected to increase at a
    CAGR of 37% from 2020 to 2025 to reach US$ 50
    billion

    Drivers and Risks Features and Trends


    Key drivers:
    • Cost Efficiency: Low cost of production and R&D boost efficiency of Indian pharma
    companies, leading to competitive export.
    • Economic Drivers: High economic growth along with increasing penetration of health
    insurance to push expenditure on healthcare and medicine in India.
    • Increasing Investments: The foreign direct investment (FDI) inflows in the Indian drugs
    and pharmaceuticals sector stood at US$ 17.75 billion between April 2000 and
    December 2020.

    Key risks:
    Counterfeit drugs, poor rural healthcare infrastructure, lack of health insurance penetration

    You might also like